Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

149.31 +1.23 (+0.83%)

Streaming Delayed Price Updated: 12:05 PM EDT, May 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

56 57 Next >

Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029 ↗

March 07, 2024

Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...

Via Benzinga

Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers ↗

March 06, 2024

Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...

Via Benzinga

Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic ↗

March 05, 2024

As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.

Via Benzinga

Novartis Reveals Promising Gene Therapy Data for Treating Spinal Muscular Atrophy in Older Children ↗

March 04, 2024

Novartis' Zolgensma gene therapy for spinal muscular atrophy latest SMART Phase 3b study reveals safety, efficacy, and significant milestones achieved. $1.21 billion sales reported in FY2023.

Via Benzinga

2 Dividend Stocks to Buy and Hold Forever ↗

February 29, 2024

These businesses look too strong to fail.

Via The Motley Fool

5 Tips to Manage Heart Health After a Heart Attack

February 23, 2024

(BPT) - By Dr. Norman Lepor

Via Brandpoint

Looking Into Novartis's Recent Short Interest ↗

February 22, 2024

Via Benzinga

3 Stocks Primed for Exponential Returns by 2034 ↗

March 01, 2024

As investors, It's always good to look at things long-term. Here are three stocks that are primed for exponential returns in ten years.

Via InvestorPlace

11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗

February 28, 2024

A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.

Via Benzinga

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

February 27, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...

Via Newsfile

Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment ↗

February 26, 2024

The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks.

Via Investor's Business Daily

This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies ↗

February 26, 2024

Results from Roche's Phase 3 OUtMATCH study on Xolair for multi-food allergies. Published in NEJM, the study reveals increased tolerance in patients aged 1-55. FDA-approved expanded use for...

Via Benzinga

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗

February 22, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Via Talk Markets

Move Over Magnificent 7, Say Hello to the GRANOLAS ↗

February 22, 2024

Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.

Via InvestorPlace

Exit Now! 3 Biotech Stocks to Sell in February 2024 ↗

February 21, 2024

These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.

Via InvestorPlace

22 Blue-Chip European Dividend Growth Stocks ↗

February 16, 2024

A discussion of insights on European dividend growth stocks.

Via Talk Markets

What The Future Holds For Google's 'Other Bets' ↗

February 16, 2024

Alphabet's far-ranging Other Bets tickle imaginations, but they've piled up huge losses. Google stock could benefit as discipline is imposed.

Via Investor's Business Daily

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗

February 15, 2024

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

Via InvestorPlace

The 3 Biotech Stocks That Could Make Your February Unforgettable ↗

February 15, 2024

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

Via InvestorPlace

Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says ↗

February 14, 2024

Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties.

Via Benzinga

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

February 14, 2024

From Erasca, Inc.

Via GlobeNewswire

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales

February 13, 2024

Via Investor Brand Network

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month ↗

February 08, 2024

Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.

Via Investor's Business Daily

JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point ↗

February 06, 2024

BeiGene's JP Morgan coverage highlights upside in valuation post-pullback. Brukinsa's success and Tevimbra's potential add to the optimism. Overweight rating, $185 price target.

Via Benzinga

Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B ↗

February 06, 2024

Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.

Via Benzinga

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion ↗

February 05, 2024

Novartis will add to its cancer treatment pipeline with via the German biotech.

Via Investor's Business Daily

Drug Maker AbbVie Stock Sees RS Rating Jump To 81 ↗

February 05, 2024

AbbVie stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81.

Via Investor's Business Daily

Why Is MorphoSys (MOR) Stock Up 50% Today? ↗

February 05, 2024

News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock.

Via InvestorPlace

MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer ↗

February 05, 2024

Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold...

Via Benzinga

3 Fabulous Dividend Stocks to Buy in February ↗

February 04, 2024

These stocks offer great dividends and more.

Via The Motley Fool

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today